Neuren chief executive Jon Pilcher told The Australian that responding to the finer points of the report was for Acadia to contemplate, and reiterated that both Neuren and Acadia were widely covered by analysts, who themselves had surveyed physicians prescribing the drug, who “all come to a different view’’.He also made the point that the Acadia share price closed up in US trade overnight, reflecting the weight investors were placing on the report. He said he did not expect Acadia to respond directly to the claims.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.100(0.80%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.44 | $12.73 | $12.13 | $11.07M | 885.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1215 | $12.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.54 | 804 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |